AI Blood Test for Colorectal Cancer Received FDA Status
The experimental blood-based screening tool has been granted Breakthrough Device Designation by the FDA.
Updated on Oct. 6, 2026 in Cancer
Live Poll
Would you prefer a blood test over a colonoscopy for routine colorectal cancer screening?
Researchers have developed an AI-based blood test for detecting colorectal cancer, which has received Breakthrough Device Designation from the US Food and Drug Administration. The test uses a predictive algorithm to identify protein and miRNA signatures from plasma samples.
Why it matters
Current colorectal cancer screening methods rely on invasive procedures that can be a barrier for some patients. Providing a blood-based alternative could improve early detection rates by making the screening process more accessible.
The study analyzed plasma samples from 3,569 participants, including a validation cohort of 2,856 patients. The test showed 65.6% sensitivity for advanced adenomas and 80.0% sensitivity for colorectal cancer specifically in the proximal colon.
The players
US Food and Drug Administration
The agency is responsible for protecting public health by ensuring the safety, efficacy, and security of human and veterinary drugs, biological products, and medical devices.
The details
The diagnostic tool relies on a combination of protein and miRNA signatures processed through an AI-derived predictive algorithm. Researchers compared these blood test results against traditional colonoscopy findings to validate the performance of the signatures.
Timeline
The findings were published on October 6, 2026.
The Big Picture
This test joins the ranks of other diagnostic tools that have secured FDA Breakthrough Device Designation to fast-track clinical evaluation. This follows the standardized trajectory of the FDA Breakthrough Devices Program, which accelerates the development of technologies for serious conditions.
This development could eventually offer a non-invasive alternative to traditional colonoscopies for routine colorectal cancer screening. Patients should discuss existing screening options with their healthcare providers until this test completes its pivotal trial phase.
The takeaway
While these initial findings demonstrate significant potential for non-invasive cancer screening, the technology remains in the investigational phase. Future clinical studies will determine whether this blood test can effectively replace or supplement the standard of care for the general population.
What happens next
The research team plans to conduct a pivotal clinical study in a larger U.S. screening cohort to further validate these findings.
Further reading
For more on the current landscape of oncology diagnostics, visit the Cancer section.
Source note: This article includes information reported by Ovid.
Live Poll
Would you prefer a blood test over a colonoscopy for routine colorectal cancer screening?
